Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH Highlights
Filter by Topic
ASH 2011 Annual Meeting
ASH 2013 Annual Meeting
ASH 2014 - Castleman's Disease
ASH 2014 - CLL
ASH 2015 - Multiple Myeloma
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
ASH 2015 – Leukemia
ASH 2017
ASH 2017 - Acute Myeloid Leukemia
ASH 2019 Wrap-up
Lirilumab plus Azacitidine in Heavily Pretreated, Relapsed AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
,
ASH Highlights
Conference Correspondent
The results of the current phase 1b/2 study showed that the combination of azacitidine plus lirilumab was well-tolerated in heavily pretreated patients with relapsed acute myeloid leukemia (AML) and poor-risk disease features.
Read Article
Venetoclax plus Decitabine or Azacitidine in Treatment-Naïve, Elderly Patients with AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
,
ASH Highlights
Conference Correspondent
An updated safety and efficacy analysis of a phase 1b study demonstrated a promising benefit–risk profile with the combination of the BCL-2 inhibitor venetoclax with either decitabine or azacitidine in elderly, treatment-naïve patients with acute myeloid leukemia (AML) who are not candidates for intensive standard induction therapy.
Read Article
Addition of Midostaurin to Standard Chemotherapy in RATIFY Decreased CIR in Patients with FLT3-Mutated, Newly Diagnosed AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
,
ASH Highlights
Conference Correspondent
The results of a post-hoc analysis of the RATIFY trial suggest that midostaurin decreases the cumulative incidence of relapse (CIR) in patients with
FLT3
mutation–positive, newly diagnosed acute myeloid leukemia (AML), with no negative impact on survival.
Read Article
Ivosidenib Monotherapy Results in Deep mIDH1 Clearance in Patients with mIDH1 AML
ASH 2017
,
ASH 2017 - Acute Myeloid Leukemia
,
ASH Highlights
Conference Correspondent
This analysis showed that ivosidenib-treated patients with
IDH1
-mutated (m
IDH1
), relapsed/refractory, and untreated acute myeloid leukemia (AML) whose best response is a complete remission (CR) or CR with partial hematologic recovery achieve m
IDH1
clearance ≤0.04%.
Read Article
R-CHOP ± Bortezomib in Patients with Untreated Non-GCB DLBCL: Results from the Phase 2 PYRAMID Trial
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
The Relevance of Minimal Residual Disease Monitoring in Elderly Multiple Myeloma Patients
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Patient Preferences on Treatment Attributes in MM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Management of Infusion-Related Reactions Associated with Daratumumab Monotherapy in RRMM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Final OS Analysis of Panorama 1 Trial of Panobinostat/Bortezomib/Dexamethasone in RRMM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Page 4 of 15
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma